MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
32.42
-0.60 (-1.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close33.02
Open33.00
Bid0.00 x 800
Ask35.00 x 1300
Day's Range32.19 - 33.15
52 Week Range31.54 - 47.82
Volume3,682,673
Avg. Volume4,627,935
Market Cap16.715B
Beta (3Y Monthly)1.18
PE Ratio (TTM)37.39
EPS (TTM)0.87
Earnings DateNov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est44.94
Trade prices are not sourced from all markets
  • Mylan Adds to Women's Healthcare Portfolio With Launch of Generic Depo-Provera® Injection
    PR Newswire12 hours ago

    Mylan Adds to Women's Healthcare Portfolio With Launch of Generic Depo-Provera® Injection

    HERTFORDSHIRE, England and PITTSBURGH, Oct. 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today announced the U.S. launch of Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL Single-Dose Vial, a generic version of the brand drug, Pfizer's Depo-Provera®. Mylan is offering Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL Single-Dose Vial to its institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).

  • What Are Pfizer’s Revenue Drivers?
    Market Realist14 hours ago

    What Are Pfizer’s Revenue Drivers?

    Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.

  • Mylan to Release Third Quarter 2018 Financial Results on November 5, 2018
    PR Newswire20 hours ago

    Mylan to Release Third Quarter 2018 Financial Results on November 5, 2018

    HERTFORDSHIRE, England and PITTSBURGH , Oct. 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its third quarter 2018 financial results, ...

  • Benzinga4 days ago

    Drug Companies To Disclose Pricing Information In Ads

    When anger over EpiPen pricing erupted in 2016, generic drugmaker Mylan NV (NASDAQ: MYL ) was villainized.  The price of the autoinjector used for severe allergic reactions was hiked by about 500 percent ...

  • Benzinga5 days ago

    Bulls & Bears Of The Week: GE, Netflix, Nike, Twitter And More

    Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included an old-school conglomerate and a social media pair. Bearish calls included an electric car maker ...

  • Here's Why Momenta Pharmaceuticals Tumbled 13.5% on Friday
    Motley Fool6 days ago

    Here's Why Momenta Pharmaceuticals Tumbled 13.5% on Friday

    The company's plan to restructure itself isn't sparking investor optimism.

  • AbbVie Permits US Sale of Sandoz's Humira Biosimilar
    GuruFocus.com7 days ago

    AbbVie Permits US Sale of Sandoz's Humira Biosimilar

    The license will take effect on Sept. 30, 2023

  • Mylan Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate Court
    PR Newswire7 days ago

    Mylan Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate Court

    Court Affirms Prior Decisions Finding Copaxone® 40 mg/mL Patents Invalid HERTFORDSHIRE, England and PITTSBURGH , Oct. 12, 2018 /PRNewswire/ -- Mylan N.V . (NASDAQ: MYL) today announced that the United ...

  • Reuters7 days ago

    U.S. appeals court upholds ruling that canceled Teva Copaxone patents

    A U.S. appeals court on Friday upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd on its blockbuster multiple sclerosis drug Copaxone. The ruling was a victory for a group of generic drug companies, including Mylan NV and Novartis AG unit Sandoz, that challenged the validity of Teva's patents in order to sell generic versions. Teva did not immediately respond to requests for comment.

  • AbbVie Settles With Novartis to Delay Humira Biosimilar in US
    Zacks7 days ago

    AbbVie Settles With Novartis to Delay Humira Biosimilar in US

    AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.

  • Investor Insights: Teva Pharmaceutical’s Valuation Multiples
    Market Realist7 days ago

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.

  • Wall Street Analysts See Upside Potential of 3.9% in TEVA
    Market Realist8 days ago

    Wall Street Analysts See Upside Potential of 3.9% in TEVA

    Teva Pharmaceutical Industries (TEVA) is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales. Teva’s growth prospects have been boosted by the FDA’s recent approval of its migraine drug. In recent months, analysts have been more confident about the company’s growth prospects. As of October 11, 24 analysts covered Teva stock and were included in a recent Reuters survey.

  • PR Newswire8 days ago

    Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data from multiple studies of YUPELRI™ (revefenacin) inhalation solution were presented at the 2018 CHEST annual meeting, which was held in San Antonio, Texas on October 6-10, 2018. The Prescription Drug User Fee Act (PDUFA) date for YUPELRI is November 13, 2018. If approved, YUPELRI would be the first and only once-daily, long-acting nebulized bronchodilator for the treatment of COPD. YUPELRI is designed to be compatible with any standard jet nebulizer.

  • Mylan Stock Falls on Analyst Downgrade, Trades at 52-Week Low
    Market Realist10 days ago

    Mylan Stock Falls on Analyst Downgrade, Trades at 52-Week Low

    Today, Morgan Stanley downgraded Mylan (MYL) from “overweight” to “equal weight.” The firm also cut its target price for MYL stock from $46 to $36. Also, Mylan has seen lower-than-expected sales from its biosimilar and complex products portfolio, which it’s increasingly focusing on in the wake of increasing generics competition and pricing pressures. Today, MYL stock fell ~2.7% during premarket trading.

  • MarketWatch10 days ago

    Mylan downgraded as previous bullish thesis is now 'broken'

    Shares of Mylan N.V. dropped 1.4% toward a one-year low in afternoon trade Tuesday, after the drug maker was downgraded at Morgan Stanley on concerns over generic sales trends, risks to EpiPen from generic competition and biosimilars strategy that's less compelling that expected. Analyst David Risinger cut his rating to equal weight, saying his thesis for upgrading the stock to overweight in March is now "broken." He lowered his stock price target to $36, which is 3.1% above current levels, from $42. Back in March 2018 when we upgraded [Mylan] from EW to OW, we expected solid growth prospects versus peers, differentiated pipeline progress and positive catalysts," Risinger wrote in a note to clients. "But newsflow has disappointed, and we fear further pressure even though we still expect Mylan to receive FDA approval of its generic Advair imminently." The stock has shed 17.7% year to date, while the SPDR Health Care Select Sector ETF has rallied 14.5% and the S&P 500 has gained 8.0%.

  • Benzinga10 days ago

    3 Headwinds Hindering Mylan

    Even with positive near-term catalysts, Mylan NV (NASDAQ: MYL ) suffers from “uncertain prospects” that warrant a neutral stance, according to Morgan Stanley.  The Rating Analyst David Risinger downgraded ...

  • GlobeNewswire10 days ago

    Mapi Pharma Presents Phase II Extension Results of Glatiramer Acetate Depot (GA Depot) at ECTRIMS 2018 in Berlin

    Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company will present two-year clinical data from its Phase II study of GA Depot for the treatment of relapsing remitting multiple sclerosis (RRMS) at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which will take place on October 10-12 in Berlin, Germany. The results will be featured as part of Poster Session #3, on Friday, October 12th, 2018, between 12:15pm and 2:15pm CET and as an e-poster.

  • Generic-Drugs Stock Outlook: No Respite from Pricing Issues
    Zacks10 days ago

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

  • PR Newswire11 days ago

    Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that data from studies of YUPELRI™ (revefenacin) will be presented at the 2018 CHEST annual meeting, being held in San Antonio, Texas on October 6-10, 2018. Researchers will also report data from a new study comparing outcomes for YUPELRI and tiotropium (Spiriva® HandiHaler®) in COPD patients with suboptimal peak inspiratory flow rates (PIFR). YUPELRI is an investigational long-acting muscarinic antagonist (LAMA) currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of COPD.

  • Johnson & Johnson Stock in the Week Ended October 5
    Market Realist13 days ago

    Johnson & Johnson Stock in the Week Ended October 5

    Johnson & Johnson: Investor Update for the Week Ended October 5Johnson & Johnson’s trading activity this week

  • GW Pharmaceuticals: Q3 Performance, Q4 Estimates
    Market Realist14 days ago

    GW Pharmaceuticals: Q3 Performance, Q4 Estimates

    GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.

  • Mylan Launches Its Generic Brevibloc Injection
    Market Realist15 days ago

    Mylan Launches Its Generic Brevibloc Injection

    Why Are Wall Street Analysts Bullish on Mylan Stock? Mylan announced the launch of its generic Brevibloc injection in single-dose bags on September 13. This is the first generic version of Baxter International’s (BAX) Brevibloc.

  • Moody's15 days ago

    Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US

    Competition from manufacturers of biosimilar drugs, or follow-on versions of complex biotech drugs, is a rising threat for branded pharmaceutical companies, Moody's Investors Service says in a new report. Branded drug makers including Roche Holding AG, Amgen Inc., AbbVie Inc. and Johnson & Johnson will see declining sales of some of their best-selling drugs over the next 12 to 18 months.

  • Mylan’s Humira Biosimilar Opportunity in Europe
    Market Realist16 days ago

    Mylan’s Humira Biosimilar Opportunity in Europe

    Why Are Wall Street Analysts Bullish on Mylan Stock? On September 20, Mylan and its partner, Fujifilm Kyowa Kirin Biologics, received the marketing authorization from the EC (European Commission) for Hulio.

  • Mylan’s Recently Launched Generic Version of Ampyra
    Market Realist16 days ago

    Mylan’s Recently Launched Generic Version of Ampyra

    On September 21, Mylan (MYL) launched its authorized generic version of Acorda Therapeutics’ (ACOR) Ampyra (dalfampridine), which is used for improvement in walking for adults who have multiple sclerosis. Mylan’s dalfampridine extended-release tablets are available in 10 mg tablets, similar to Acorda’s Ampyra. On September 21, MYL stock rose ~2.2% before closing up ~0.67% over the previous day’s closing price.